Exosomes derived from human umbilical cord MSCs rejuvenate aged MSCs and enhance their functions for myocardial repair

Ning Zhang¹,²†, Jinyun Zhu¹,²†, Qunchao Ma¹,², Yun Zhao¹,², Yingchao Wang¹,², Xinyang Hu¹,², Jinghai Chen¹,², Wei Zhu¹,², Zhongchao Han³ and Hong Yu¹,²*

Abstract

Background: Age and other cardiovascular risk factors have been reported to impair the activities of mesenchymal stem cells (MSCs), which will affect the efficacy of stem cell transplantation. The objective of the study is to investigate whether exosomes derived from human umbilical cord MSCs (UMSCs) could enhance the activities of bone marrow MSCs from old person (OMSCs), and improve their capacity for cardiac repair.

Methods: Exosomes extracted from conditioned medium of UMSCs were used to treat OMSCs to generate OMSCs Exo. The key molecule in the exosomes that have potential to rejuvenate aged MSCs were screened, and the role of OMSC was tested in the mouse model of myocardial infarction (MI).

Results: We found the activity of senescence-associated β-galactosidase and the expression of aging-related factors such as p53, p21, and p16 were significantly higher in OMSCs than those in UMSCs. After treatment with UMSC exosomes, these senescence phenotypes of OMSCs were remarkably reduced. The proliferation, migration, differentiation, and anti-apoptotic and paracrine effect were increased in OMSCs Exo. In vivo study, mice with cardiac infarction had significantly better cardiac function, less fibrosis, and more angiogenesis after they were injected with OMSCs Exo as compared with those with OMSC. There was more miR-136 expression in UMSCs and OMSCs Exo than in OMSCs. Upregulation of miR-136 by transfection of miR-136 mimic into OMSCs significantly attenuated the apoptosis and senescence of OMSCs. Apoptotic peptidase activating factor (Apaf1) was found to be the downstream gene that is negatively regulated by miR-136 via directly targeting at its 3’UTR.

Conclusion: Our data suggest that exosomes from young MSCs can improve activities of aged MSCs and enhance their function for myocardial repair by transferring exosomal miR-136 and downregulating Apaf1.

Keywords: Mesenchymal stem cells, Exosomes, Rejuvenation, MicroRNA, Myocardial infarction
Background

Stem cell-based transplantation is one of the most promising strategies of regenerative medicine for the treatment of different diseases, such as cardiovascular diseases [1, 2]. At present, mesenchymal stem cells (MSCs) are the most used cell type for treating various diseases. Given that allogenic MSCs have the risk of immunogenicity, especially for the elderly patient, patient-derived autologous MSCs may be the safer choice in terms of avoiding unwanted immune responses [3, 4]. Unfortunately, age and other cardiovascular risk factors have been reported to reduce the availability of stem cells and to impair their function and activity [5, 6], thus limiting their therapeutic usefulness in the aged patients who could most benefit. Therefore, strategies to ameliorate the biological phenotype and function of MSCs from old people (OMSCs) are urgently needed to achieve higher therapeutic efficacy when autologous MSCs are used.

The current paradigm is that MSCs accomplish many of these therapeutic functions via a paracrine mechanism [7]. Paracrine effects are typically mediated by bioactive components that are present in secreted membrane vesicles [8]. Cellular senescence not only impacts the cell function, but also influence their neighboring cells through secreting high levels of inflammatory cytokines, chemokines, growth factors, and metalloproteinases, which is so-called senescence-associated secretory phenotype (SASP) [9, 10]. In contrast, young cells have been shown to be able to rejuvenate aged cells through secreting “young signals” [11]. Recent study showed that extra-cellular vesicles (EVs) derived from either induced pluripotent stem cells (iPSCs) or MSCs can alleviate senescence of human cells in vitro [12]. It suggests that paracrine factors of MSCs may play an important role in the anti-aging process. Thus, the EVs secreted from young cells appear to be a novel anti-aging factor. As a major part of EVs, exosomes become a research focus. Exosomes are biological nanovesicles of 30–120 nm in diameter and are part of EVs, exosomes become a research focus. Exosomes containing a wide range of contents including nucleic acids, proteins, lipids, mRNAs, and miRNAs [13, 14]. The paracrine effects exerted by human umbilical cord MSCs (UMSCs) are more intense than those exerted by bone marrow stem cells (BMSCs) and adipose-derived MSCs [15, 16]. However, the rejuvenation effect of exosomes secreted from UMSCs remains unclear and the mechanism remains to be clarified.

A growing number of studies have already confirmed that exosomal miRNAs play important roles in mediating intracellular cell communication. MicroRNAs are a class of small (18 ~ 22 nucleotides) single-stranded non-coding RNAs that suppress the expression of protein-coding genes by directing translational repression, mRNA degradation, or both. miRNAs mediate their regulatory action through imperfect binding to the 3’-untranslated region (3’-UTR) of target mRNAs carrying the complementary site [17]. Clinically, profiles in exosomes have been linked to disease pathologies including the aging process [18].

Here, we hypothesize that exosomes derived from UMSCs (ExoUMSCs) can rejuvenate OMSCs via transferring specific miRNAs, resulting in higher activities of OMSCs for myocardial repair. In this study, we found that ExoUMSCs can ameliorate senescent phenotype and improve functions of OMSCs by releasing exosomal miR-136 which down-regulates apoptotic peptidase activating factor (Apaf1) in OMSCs. Such rejuvenated OMSCs can have better therapeutic effect for cardiac repair.

Our study sheds new light on the cell-free modification of aged stem cells as a potential therapeutic tool for tissue regeneration.

Methods

Human samples of umbilical cord blood and bone marrow

The research proposal for use of human samples was approved by the Second Affiliated Hospital Research Ethics Committee of Zhejiang University and in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Before samples were collected, all participants received and signed the written informed consent. Bone marrows from proximal femur of male patients at the age of 65 to 85 years were used. The human umbilical cord blood of newborn babies (n = 9) and the circulating blood of adult males (n = 29, age at 40–89 years old) were collected at the Second Affiliated Hospital of Zhejiang University (Hangzhou, China).

Isolation and identification of MSCs

Human umbilical cord MSCs (UMSCs) were provided by National Engineering Research Center of Cell Products, State Key Laboratory of Experimental Hematology (Tianjin, China). Bone marrow MSCs were isolated from the bone marrow. Bone marrows obtained from the human proximal femur were washed with phosphate buffered saline (PBS) and separated by the isolation reagents (Wealthlin Science and Technologies, Toronto, Canada) according to the user’s guide. The collected cells were seeded into 75 cm² culture flasks with low glucose Dulbecco’s modified Eagle’s medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS; Life Technologies) and 100 U/ml penicillin/streptomycin (v/v) (SP) in a humidified atmosphere with 95% air/5% CO₂ at 37 °C. After 48–72 h culture, non-adherent cells were removed by changing the medium. The medium was changed every 2–3 days. Cells were passed when cells reached ~ 80%
confluence and MSCs at passage 2–6 were used for the study. MSCs were characterized for their surface markers by a FACS Canto II Flow Cytometer (BD Bioscience, San Jose, CA, USA). Briefly, $1 \times 10^6$ cells were collected and suspended in 100 μl PBS with 1% FBS, and then incubated with fluorescence-labeled antibodies against the surface markers (mesenchymal surface markers: PE-CD29, PE-105, APC-CD166; endothelial cell surface marker: FITC-CD34; hematopoietic surface marker: FITC-CD45 and isotype-matched control) for 1 h (Fig. S1B). After washed with PBS twice, the cells were analyzed for the cell surface markers using FACS via software (BD Bioscience).

**Exosomes isolation and identification**
Exosomes were isolated using differential centrifugation according to the described methods. UMSCs ($1 \times 10^6$ cells) were seeded on the 75 cm$^2$ culture flasks with DMEM containing 10% (v/v) FBS and 100 U/ml SP in a humidified atmosphere at 37 °C. Once cells were passed at 80–90% confluence ($\sim 1 \times 10^7$ cells), UMSCs were washed with PBS twice and cultured in the same volume of DMEM with exosome-removed serum for 48 h. The supernatant was harvested and centrifuged at 300×g for 10 min and 10,000×g for 30 min to discard the dead cells. The supernatant was concentrated in a Concentrator with 100KD MW cutoff under centrifugation at 2500×g for 10 min for several times. The concentrated supernatant was then centrifuged at 100,000×g for 70 min to get exosome pellet which was resuspended in PBS and centrifuged again under 100 μl PBS and stored at −80 °C. A total 20 T75 flasks of UMSCs ($\sim 20 \times 10^7$ cells) were used to achieve the final $\sim 60 \mu g$ exosomes that were resuspended in 100 μl PBS. The morphology of exosomes was visualized by transmission electron microscope (TEM). The size distribution of exosomes was measured by dynamic light scattering (DLS) with a Nanosizer™ instrument (Malvern, UK).

**Animal experimental**
Myocardial infarction (MI) model was established on 6–8-week male C57BL/6 mice. Thoracotomy was performed at the fourth intercostal space to expose the heart and left anterior descending coronary artery (LAD). The peri-infarct myocardial region was injected at five different points with a total 30 μl PBS with or without $1 \times 10^6$ MSCs using a 30-gage needle. In the sham-operated mice, LAD was not ligated. The mice were randomly separated into 5 groups: sham, DMEM, OMSCs, OMSCsExo, and UMSCs.

**miRNA mimic transfection**
Cells ($1 \times 10^5$) were seeded in 12-well plates the day before transfection. The cells were transfected with 50 nM of miR-136 mimic and its non-specific miRNA negative control (Ambion, Austin, TX, USA), using Lipofectamine 3000 as the manufacture’s instruction (life science). MiR-136 expression in the transfected cells was determined by RT-qPCR at 48 h after transfection.

**Plasmid construction and luciferase activity assay**
Luciferase activities were measured by a Dual-Glo Luciferase Reporter Assay Kit (Promega). To elucidate whether Apaf1 was a target gene of miR-136, TargetScan (http://targetscan.org) and miRTarBase (http://miRTarBase.mbc.nctu.edu.tw) were used to predict the target genes that may be regulated by miRNA molecules. Apaf1 was identified as a potential target which can be regulated by miR-136. Bioinformatic analysis identified two putative binding sites of miR-136 at positions 138–145 and 1091–1098 of Apaf1 3’UTR. Wild-type (WT) and mutant binding regions of miR-136 in the 3’UTR of Apaf1 gene were cloned into pMIR-REPORT luciferase reporter plasmids (Invitrogen, USA). Four plasmids were generated: (1) WT, (2) mutation 1 at positions 138–145, (3) mutation 2 at positions 1091–1098, and (4) dual mutations at both sites of 3’UTR of Apaf1 gene. These plasmids were individually cotransfected with miR-136 mimic (100 nM; Sangon Biotech Co. Ltd., Shanghai, China) or negative control mimics into HEK293T cells (ATCC, Manassas, VA, USA). Renilla luciferase reporter plasmids were transfected as an internal positive control. After cultivation at 37 °C for 24 h, cells were assayed using the dual-luciferase assay system (Promega, Madison, USA) according to the manufacturer’s instructions. All assays were repeated at least three times.

**Statistical analysis**
Data are presented as mean ± standard deviation (SD). All the data were analyzed with GraphPad Prism 6.02 software (San Diego, Calif). Continuous variables were compared by the Student $t$ test. A comparison of more than two groups was performed by one-way ANOVA. A value of $P < 0.05$ was considered significant.

**Results**
MSCs from elderly are senescent and functional defective
To understand the properties of MSCs from the elderly (OMSCs), we first compared senescent phenotypes of OMSCs (> 65 years old) with MSCs from the umbilical cord (UMSCs). As expected, more senescence-associated β-gal-positive cells were observed in OMSCs than in UMSCs (Fig. 1a, b). In line with these, the senescence-related markers p53, p21, and p16 were markedly upregulated and longevity marker Sirt1 was significantly decreased in OMSCs (Fig. 1c). Consistent with these results, the proliferation of OMSCs was significantly reduced as compared to that of UMSCs (Fig. 1d).
Altogether, these data showed that OMSCs have significant senescent phenotypes, leading to a functional defection.

Exosomes derived from UMSCs ameliorate senescent phenotype of OMSCs

Exosomes from UMSCs (Exo UMScs) were purified from the conditioned medium of UMSCs. The morphology of Exo UMScs was typical cup-shaped with double-layer membrane structure as visualized by transmission electron microscopy (TEM) (Fig. 2a). Western blot analysis confirmed that the isolated particles expressed exosome-specific markers: CD63, CD9, and Alixs (Fig. 2b). The particle size of Exo UMScs was around 60–150 nm as shown by dynamic light scattering (DLS) (Fig. S2). After OMSCs were incubated with Dil-labeled Exo UMScs for 48 h, fluorescence was detected inside the cells (Fig. 2c), indicating that Exo UMScs were efficiently internalized into the target cells. A number of β-gal-positive cells were significantly reduced in OMSCs after treated with Exo UMScs (Fig. 2d). Expression of aging-related factors p53, p21, and p16 was also markedly reduced, and the level of Sirt1 was increased in the Exo UMScs-treated OMSCs (Fig. 2e). The growth rate of OMSCs was significantly increased (Fig. 2f), and more OMSCs entered into S phase of cell cycle after treatment with Exo UMScs (Fig. 2g). The numbers of EdU-positive OMSCs were significantly higher in the Exo UMScs-treated OMSCs than the untreated cells (Fig. 2h). These results indicate that the exosomes secreted by UMSCs can rejuvenate the senescent MSCs.

Exo UMScs renewed biological activities of OMSCs

To examine if Exo UMScs could improve biological functions of OMSCs, OMSCs were pretreated with Exo UMScs for 48 h (OMSc Exo). The migration capacity was remarkably increased in OMSCs Exo measured by either Transwell assay (Fig. 3a) or scratch wound assay (Fig. S3a-d). The lower levels of Bcl-2/bax confirmed the decreased apoptosis of Exo UMScs-treated OMSCs (Fig. 3b). Furthermore, a reduced number of apoptotic cells were observed in the Exo UMScs-treated OMSCs (Fig. 3c) as compared with the untreated cells, and the rate of apoptotic cells was almost equivalent to that of UMSCs under the stressed condition.
**Fig. 2** (See legend on next page.)
The differentiation potential of OMSCs into osteocytes, chondrocytes, and adipocytes was also increased after treated with Exo\textsuperscript{UMSCs} (Fig. S4).

Since the therapeutic effects of MSCs are primarily contributed by their paracrine functions, the effect of Exo\textsuperscript{UMSCs} on MSC paracrine functions was also studied. The conditioned media were collected from OMSCs, OMSCs\textsuperscript{Exo}, and UMSCs to treat human umbilical vein endothelial cells (HUVECs) and primary mouse cardiomyocytes for assessing the pro-angiogenesis and anti-apoptosis effect of MSCs. Significantly increased tube formation was observed in HUVECs treated with the medium of OMSCs\textsuperscript{Exo} as compared with those treated with DMEM or medium of OMSCs (Fig. 3d). Similarly, the apoptosis rate of cardiomyocytes (CMs) under hypoxia and serum deprivation condition was attenuated after CMs were treated with the medium of OMSCs\textsuperscript{Exo} as compared with DMEM or OMSC groups, and reached a similar level as that of treated with the medium of UMSCs (Fig. 3e). These results suggested that exosomes secreted by UMSCs can ameliorate the biological function of OMSCs and enhance their paracrine effects.

OMSCs pretreated with Exo\textsuperscript{UMSCs} have better cardioprotective effect in vivo

To investigate the effect of Exo\textsuperscript{UMSCs} on therapeutic functions of OMSCs for cardiac regeneration after myocardial infarction (MI), OMSCs or OMSCs\textsuperscript{Exo} treated with or without Exo\textsuperscript{UMSCs} were injected into myocardium immediately after MI. We measured cell survival after MSC transplantation in the heart tissue from different groups at day 7 after myocardial infarction, and found that the survival of UMSC and OMSC\textsuperscript{Exo} were significantly higher than those of the OMSC and DMEM groups (P < 0.05). There was an increased trend in survival rates of UMSC compared with OMSC\textsuperscript{Exo} (Fig. S5).

We measured and analyzed the immune cells including CD3\textsuperscript{+} T cells, CD19\textsuperscript{+} B cells, Ly6G\textsuperscript{+} neutrophils, F4/80\textsuperscript{+} macrophages, and inflammatory factors such as IL-1b, IL-6, IL-12, TNFa, and MCP-1 in the heart tissue from different groups at day 7 after myocardial infarction. No differences in the amount of immune cells and inflammatory factors are detected between OMSC and UMSC groups (Fig. S6).

Significant improvement in cardiac functions, both ejection fraction (EF\%) and fractional shortening (FS\%), was found in the OMSCs\textsuperscript{Exo} group as compared with the OMSC group (EF 56 ± 5\% vs 45 ± 12\%, p < 0.05; FS 29 ± 3\% vs 22 ± 7\%, p < 0.05) (Fig. 4a), while OMSC treatment also resulted in certain improvement in cardiac function as compared with the control mice treated with DMEM (EF 45 ± 12\% vs 34 ± 7\%, p < 0.05; FS 22 ± 7\% vs 16 ± 4\%, p < 0.05). The cardioprotective effect of OMSCs\textsuperscript{Exo} reached close to that of UMSCs (Fig. 4b). The density of CD31\textsuperscript{+} capillary and vWF\textsuperscript{+} cells were significantly increased in mice injected with OMSCs\textsuperscript{Exo} (Fig. 4c, d and Fig. S7) as compared with those injected with UMSCs or DMEM 28 days after infarction. Similar trends were observed in arteriole density as measured by α-SMA staining (Fig. 4e, f). The scar size at 28 days after MI was significantly smaller in the OMSCs\textsuperscript{Exo} group than that of the OMSC and DMEM groups (Fig. 4g, h). These results indicate an improvement in therapeutic functions of OMSCs after treated with Exo\textsuperscript{UMSCs}.

miRNA-136 was a key effector of Exo\textsuperscript{UMSCs} to rejuvenate OMSCs

To study the mechanism of Exo\textsuperscript{UMSCs}-mediated rejuvenation of OMSCs, the profiles of age-related miRNAs were screened from database (Miranda and TargetScan) and literatures [19, 20] as most of the effects of exosome were carried out through exosomal miRNAs. Among these miRNAs, miR-136 was the most abundant in UMSCs, as compared with OMSCs, and was increased more than 20-fold in OMSCs after cultured with Exo\textsuperscript{UMSCs}, whereas no significant difference was observed for other miRNAs such as miR-106a, miR-155, and miR-29C among these groups (Fig. 5a, Fig. S8). Moreover, the level of miRNA-136 in Exo\textsuperscript{OMSCs} was also higher than that in Exo\textsuperscript{UMSCs} (Fig. 5b). Next, we examined the role of miR-136 in regulating OMSC
senescence and biological function. The mRNA and protein levels of senescent-associated markers p53, p21 and p16 (Fig. 5c, d), as well as the β-gal* cells, were markedly reduced in OMSCs after transfected with miR-136 mimics (Fig. 5e). As a hallmark of cellular senescence and DNA damage, γH2AX-positive foci were enriched in OMSCs, as compared with UMSCs, and were remarkably decreased in miR-136 transfected OMSCs (Fig. 5f).

Furthermore, using an EdU incorporation assay to measure DNA synthesis, we found that the proliferation rate of
OMSCs was also significantly increased after OMSCs were transfected with miR-136 mimic (Fig. 5g and Fig. S9a). More cells at S phase of cell cycle (Fig. 5h and Fig. S9b) and less apoptotic cells (Fig. 5i and Fig. S10a-c) were observed in the miR-136 overexpressed OMSCs in comparison with the original OMSCs. ExoUMSCs and miR-136 mimics also significantly increased the cell survival rate (Fig. 5j) under hypoxia and serum deprivation condition (Fig. S11) mimicking the microenvironment of MI in vivo, and resulted in a similar viability as that of UMSCs.
Apaf1 is a functional direct target of miR-136 involving in OMSC survival

To understand how miR-136 regulates functions of OMSCs, the downstream target of miR-136 in regulating cell senescence and survival was searched from literatures and confirmed via bioinformatic software (Miranda and miRTarbase). Apoptotic peptidase activating factor 1 (Apaf1) gene was found to be one of the predicted target genes for miR-136, and Apaf1 has been reported to play a crucial role in regulating cell survival and apoptosis [21]. The expression of Apaf1 mRNA in OMSCs is higher than that in UMSCs (Fig. 6a). When OMSCs were treated with agonist (MDK83190) of Apaf1, the level of aging-related factors p53, p21, and p16 were up-regulated and the level of Sirt1 was downregulated, whereas the inhibitor (ZYX-488) of Apaf1 reversed this phenomenon (Fig. 6b). The data confirm that Apaf1 negatively affects cell aging.

We then examined the expression of Apaf1 in OMSCs after treated with ExoUMSCs or miR-136 mimic. Declined level of Apaf1 mRNA was observed in ExoUMSCs-treated or miR-136-transfected OMSCs, as compared with
Fig. 6 (See legend on next page.)
untreated OMSCs or miR-NC transfected OMSCs, respectively (Fig. 6c). In agreement with this, Apaf1 mRNA was increased in UMSCs after treated with miR-136 inhibitor. These results confirmed that the expression of Apaf1 was negatively regulated by miR-136.

Two putative binding sites of miR-136 were identified at 3′UTR of Apaf1 (positions 138–145 and 1091–1098) through bioinformatic analysis (Fig. 6d). To ascertain miR-136 directly binds to the 3′UTR of Apaf1 and causes translational inhibition, such two predicted 3′UTRs of Apaf1 and their mutants were cloned into a luciferase reporter construct pmirGLO (Fig. 6d). The luciferase assay revealed that miR-136 mimic significantly reduced the activity of luciferase when the reporter gene was fused with the Apaf1 3′UTR, as compared with the miR-NC (Fig. 6e). The mutation of both putative miR-136 sites in the 3′UTR of Apaf1 abrogated the effect of miR-136 on luciferase activity, while single mutation could not achieve such abrogation. Expressions of APAF1 protein and its downstream target caspase 9 were both suppressed in OMSCs after transfection with miR-136 mimic (Fig. 6f). These results indicated that Apaf1 is the downstream effector of miR-136 through directly binding at the two sites of the 3′UTR region.

More miR-136 in cord blood than in adult circulation
To investigate the expression of miR-136 during aging, blood from 29 healthy male adults (age > 40 years) and umbilical cord blood from 9 healthy maternity as the young group were collected, and the level of miR-136 in the plasma was measured by qRT-PCR. The expression level of miR-136 was significantly higher in cord blood than that in blood from adults (Fig. S12).

Discussion
MSCs hold significant promise for regenerative medicine. Although transplantation of allogenic MSCs such as MSCs derived from perinatal tissues has been widely accepted, infusion of allogenic MSCs from donors can often trigger immunoreaction, such as memory T cell response [22–24], whereas autologous MSCs can avoid such immune reaction since autologous MSCs have no or low immunogenicity [25]. However, aging and its associated diseases negatively impact MSC properties in terms of proliferation, paracrine function, and differentiation and impair their therapeutic effect when autologous MSCs are applied for old patients [26]. It has great clinical significance to restore the activity of aged MSCs for unrestricted stem cell transplantation. Physical [27], genetic, and biochemical [28] ways have been used to rejuvenate stem cells.

Here we found that exosomes derived from young MSCs (ExoUMSCs) ameliorate the senescence phenotype of OMSCs. The cell proliferation, mobility, and paracrine activity were significantly enhanced in OMSCs after ExoUMSCs treatment. Such rejuvenated OMSCsExo had significantly increased activities in cardiac repair. Injection of OMSCsExo into infarct heart resulted in better cardiac function, more neovascularization, and less scar formation in comparison with that of OMSCs, which is consistent with the strengthened paracrine effects in vitro. More importantly, we for the first time identified the key factor achieving the rejuvenation: miR-136 and its target gene Apaf1. There are more miR-136 in both UMSCs and ExoUMSCs than in OMSCs. After treatment with ExoUMSCs, the miR-136 level in OMSCsExo was significantly increased. Either ExoUMSCs or miR-136 mimic can downregulate the expression of Apaf1 in OMSCs, resulting in enhanced functions of OMSCs. These results suggest a novel approach to rejuvenate aged MSCs and renew their activities for tissue repair. The significance of this study is to expand the source of human MSCs and found a simple and safe alternative method to improve the therapeutic efficacy in cardiac disease. The novel method for rejuvenation of aged MSCs can also be expanded to broad clinical use for cell transplantation.

Exosomes are extracellular vesicles (EVs) with a size range of 30–120 nm and originate from the endosomal compartment where intraluminal vesicles within
multivesicular bodies are released by exocytosis [29]. Exosomes can be secreted from almost all cell types and are found in most human biological fluids, including plasma, urine, synovial fluid, and bronchial lavage fluid [30]. Exosomes have emerged as novel and important players in intercellular communication, mainly through their ability to transfer biological content, consisting of proteins, mRNAs, miRNAs, and other non-coding RNAs, to recipient cell. Hence, exosomes have been identified as key mediators of paracrine effects, both in physiological and pathological states associated with aging. Recent researches have focused on exosomes as a powerful therapeutic tool in tissue repair and regeneration. Microvesicles from young MSCs were able to rejuvenate aged murine hematopoietic stem cells [31, 32]. Another research found that EVs secreted from human MSCs can reduce cellular ROS levels and alleviated aging. Recent researches have focused on exosomes as a powerful therapeutic tool in tissue repair and regeneration. Microvesicles from young MSCs were able to rejuvenate aged murine hematopoietic stem cells [31, 32]. Another research found that EVs secreted from human MSCs can reduce cellular ROS levels and alleviated aging phenotypes of senescent MSCs [33]. These studies have provoked great interest in examining the roles of EVs in cellular senescence and aging. However, these studies failed to illustrate the mechanism of such a rejuvenation effect of EVs.

In our study, we used human umbilical cord MSCs as a secretory source for the "young exosomes". UMSCs have superiorities, including low immunogenicity, non-invasive procedure for harvest, and easy expansion in vitro, and have been used widely in tissue repair and regeneration. In comparison with MSCs derived from other human tissues such as the bone marrow and adipose, UMSCs were the best in terms of cell proliferation and paracrine effect and had the lowest expression of senescent markers: p53, p21, and p16. It has been reported that UMSC-derived exosomes activated several signaling pathways, which are conducive in cardioprotection [34]. Exosomes from UMSCs had also been used to rejuvenate the human skin [35].

Senescence has been initially characterized in vitro as a process limiting the proliferative capability of primary cells. The proliferation arrest, a main feature of cell senescence, is accompanied by changes in both morphology and function. Our study found that after Exosome treatment, more cells entered into S phase and continued proliferation, while the aged MSCs were mostly in the stationary phase. Exosome treatment reduced the senescence phenotypes and rejuvenated the activity of aged MSCs. In vivo, OMSCs were better than OMSCs in promoting neovascularization around the infarct zone, reducing cardiac fibrosis and preventing cardiomyocytes from apoptosis. The strengthened paracrine effect of OMSCs reached a similar level to that of UMSCs. Our work greatly expands the future application regimen of different human MSCs since rejuvenation by exosomes is a safer and more convenient way in comparison with other regents or genetic modification. However, it is still unknown if the functional improvement of aged stem cells is permanent by the exosomal treatment. Long-term effect of exosomes on MSCs is yet to be evaluated.

MicroRNAs (miRNAs) have been identified as the key post-transcriptional repressors of gene expression in various cells and participate in multiple biological processes, including aging and cell survival process [36]. Through direct exosomal transferring, miRNAs in the recipient cells were changed along with their functions [37]. However, early studies did not shed light on how EVs from human stem cells alleviate the aging phenotypes on senescent cells. Our current studies provided strong evidence for a new mechanism that UMSCs and their exosomes carry a high level of miR-136 which plays a major role for amelioration of aging phenotypes and viability when it was transferred into OMSCs.

MiR-136 was initially identified by cloning studies in mouse, and later verified in human embryonic stem cells [38]. Researches have shown that miR-136 acts as an anti-carcinoma miRNA in lung [39] and hepatocellular carcinoma [40], and involves the metastasis of colon cancer by suppressing epithelial-to-mesenchymal transition [41]. Here, we showed that both the cellular and exosomal level of miR-136 were higher in UMSCs than in OMSCs. After OMSCs were treated with Exosome or transfected with miR-136 mimic, γH2AX foci, a marker of DNA damage and repair, was significantly reduced in OMSCs, and less cell apoptosis of OMSCs was detected under stressed culture condition. We also unveiled the mechanism of miR-136 in the rejuvenation of OMSCs by identifying that miR-136 is a regulator of Apaf1. Luciferase assay and Western blot assay confirmed that miR-136 negatively regulates Apaf1 expression via directly targeting its two sequences at 3’ UTR.

The association between miR-136 and Apaf1 has not been reported before. Especially, the role of miR-136/Apaf1 signaling in the regulation of senescence and activities of aged cells was unknown. Our results showed that UMSCs derived exosomes regulate aging-related phenotypes and functions in a miR-136/Apaf1-dependent way. Apaf-1 is a key molecule in the intrinsic pathway of apoptosis. It oligomerizes in response to cytochrome C release and forms a large complex known as apoptosome [42]. As the initiator caspase component of the apoptosome complex, procaspase-9 is recruited and activated by the apoptosome and leads to downstream caspase-3 processing [43]. It has been reported that Apaf-1 protein levels were controlled at post-transcriptional levels, which appears to be regulated at least to some extent by microRNAs, such as miR-23 and miR-27 in the central neural system [44]. In addition, co-transduction of Apaf-1 and caspase-9 triggers p53-dependent signaling pathways, and
increased DNA damage contributing to cellular senescence was observed Casp 9- and Apaf1-deficient cells [45–47]. In our study, Apaf1 expression was inhibited by either ExoUMSCs or miR-136 mimic. The level of caspase 9, a downstream target of Apaf1, was also declined. Besides its fundamental role in the apoptotic cell death pathways, Apaf-1 has a modulator effect on cell-cycle during DNA damage. Intriguingly, we found that there were more cells into S phase of cell-cycle after the cells were transfected with miR-136 mimics, which indicated that miR-136 and its downstream targets are involved in the cell proliferation and survival. In addition to apoptotic functions, non-apoptotic functions for Apaf-1 are emerging [48, 49]. Herein, mapping the interplay between these functions is essential for a complete understanding of the roles of Apaf-1 in health and aging diseases. Despite our novel finding of exosome-delivered miR-136 as a key element for rejuvenation, it remains unclear whether additional bioactive molecules (proteins, RNAs, lipids, etc.) are involved in the alleviation of senescence in OMCSs. It is undeniable that the effect of exosomes on aging cannot be achieved by a single miRNA.

In addition, we compared miR-136 level in the serum of the umbilical cord and adults, and found that miR-136 expression was higher in umbilical cord serum, which is consistent with the recent report about miRNA in circulating microvesicles as biomarkers for age-related cognitive decline [50]. Our results pave the way for the use of exosomal miR-136 as a biomarker for diagnosis.

Conclusion
Our study reveals a new approach to reactive senescent cells through exosomes. We reported for the first time that exosomes secreted from young MSCs could effectively alleviate the senescent properties of aged MSCs and enhance their therapeutic effect. The key rejuvenation factor in ExoUMSCs is miR-136 which directly binds to the 3′ UTR of Apaf1 mRNA and suppresses Apaf1 expression in the recipient cells. Rejuvenation of aged stem cells with an effective, convenient, and safe method could expand the availability of the donor for various applications (Fig. 6g). Our results point out miR136, as a key element released by young cells in the extracellular environment via exosomes, can improve surrounding cell viabilities, suggesting that we can reverse aging through miRNA gene editing. It is possible that epigenetic changes of aging hallmarks through exosomes or miRNAs could alter the physiological aging process and provide a key target for future rejuvenation.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13287-020-01782-9.

Additional file 1: Table S1. Name and sequence of primers sets for real-time RT-PCR
Additional file 2: Table S2. Echocardiographic parameters of mice with indicated treatment (28d post-MI).
Additional file 3: Table S3. Construction of four luciferase reporter plasmids with different 3′ UTR binding sites of Apaf1 gene.
Additional file 4: Figure S1. Characteristics and identification of OMCSs and UMSCs. Morphology of UMSCs and OMCSs were observed under microscope. MSCs were identified by flow cytometry with positive cell surface markers CD29, CD44, CD90, and negative for CD34 (endothelial cell marker) and CD45 (hematopoietic marker).
Additional file 5: Figure S2. Apoptosis of OMSCs after transfection of miR-136 or treatment with ExoUMSCs. OMSs were analyzed for cell cycle by EdU staining kit and flow cytometry analysis.
Additional file 6: Figure S3. Migration assay of MSCs. Mobility of OMCSs with or without treatment of ExoUMSCs was analyzed by the transwell assay. Migrated cells were visualized by crystal violet staining.
Additional file 7: Figure S4. Differentiation potential of OMCSs after treatment with ExoUMSCs. Representative images of Size distribution range (50-150 nm) of ExoUMSCs was assessed by DLS analysis.
Additional file 8: Figure S5. Cell survival after transplantation after MI. Flow cytometric analysis of Dil positive MSCs injected in the peri-infarct myocardial region after myocardial infarction in different groups.
Additional file 9: Figure S6. Apoptosis of OMSCs after transfection of miR-136 or treatment with ExoUMSCs. Apoptotic OMSs were detected by Annexin V/PI staining and TUNEL staining which treated with ExoUMSCs or transfected with miR-136 mimic or miR-NC were analyzed for cell cycle by EdU staining kit and flow cytometry analysis.
Additional file 10: Figure S7. Effects of MSCs Transplantation on angiogenesis after MI. Representative images of immunofluorescence staining for arterioles using shp against vWF (red) to illustrate matured vessel in the hearts. Scale bar,100 μm. vWF positive cells were quantified per HFF to calculate the matured vessel density in a bar graph.
Additional file 11: Figure S8. MRNAs expression in MSCs. The expression of miR-17, 19a, 10a, 29, 136, and 155 in OMCSs, OMSs treated with ExoUMSCs, and UMSCs were assessed by RT-qPCR. U6 was used as an internal reference gene.
Additional file 12: Figure S9. Detection of OMSCs proliferation and cell cycle after treatment with ExoUMSCs or miR-136. OMSs were analyzed for cell cycle by EdU staining kit and flow cytometry analysis.
Additional file 13: Figure S10. Apoptosis of OMSs after transfection of miR-136 or treatment with ExoUMSCs. Apoptotic OMSs were detected by Annexin V/PI staining and TUNEL staining which treated with ExoUMSCs or transfected with miR-136 mimic or miR-NC were analyzed for cell cycle by EdU staining kit and flow cytometry analysis.
Additional file 14: Figure S11. Quantification of viability of OMSs. Cell viability of OMSs with specified treatments was assessed by CCK-8 assay under serum deficiency.
Additional file 15: Figure S12. More miR-136 in cord blood than in adult circulation. Quantification of miR-136 level in serum from adults (n = 29) and cord blood of healthy maternity (n = 9) by real time PCR. U6 was used as an internal reference gene for miRNA.

Abbreviations
BMSCs: Bone marrow stromal stem cells; FBS: Fetal bovine serum; UMSCs: Mesenchymal stem cells; OMSC: Mesenchymal stem cells from old
person; Apaf1: Apoptotic peptidase-activating factor; SASP: Senescence-associated secretory phenotype; EVs: Extracellular vesicles; TEM: Transmission electron microscopy; DLS: Dynamic light scattering; MI: Myocardial infarction; LAD: Left anterior descending coronary artery; 3’UTR: 3’-untranslated region; ExoR1/2/3: Exosomes from mesenchymal stem cells; HUVEC: Human umbilical vein endothelial cell; MSCs: Mesenchymal stem cells were pretreated with exosomes; vWF: von Willebrand Factor; CM: Cardiomyocyte; EF: Ejection fraction; FS: Fractional shortening; DMEM: Dulbecco’s modified Eagle’s medium

Acknowledgments
Not applicable.

Authors’ contributions
NZ, JYZ, and YCW performed the experiments, analyzed the data, and prepared the manuscript. NZ and QCM analyzed the data and prepared the figures. NZ and YZ performed bioinformatics and statistical analyses. ZCH provided MSCs from the umbilical cord. HY and ZCH designed the experimental study and revised the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China Grant (No. 81570251, 81528002 to HY), the National Natural Science Youth Foundation of China Grant (No.18700424 to QCM), and Science and Technology Project of Zhejiang Provincial (No. 2017C37075 to YCW).

Availability of data and materials
The datasets generated and/or analyzed during the current study are available in the Mendeley repository: Zhang, Ning; Zhao, Yun; Zhu, Jinyun; Ma, Quanchao; Wang, Yingchao; Hu, Xinyang; Zhu, Wei; Han, Zhongchao; Yu, Hong (2019), “figshare”, Mendeley Data, V4, http://dx.doi: https://doi.org/10.17632/fp4njbdwt.4

Ethics approval and consent to participate
The animal protocols used in this study and revised the manuscript. All authors read and approved the final manuscript.

Availability of data and materials
The datasets generated and/or analyzed during the current study are available in the Mendeley repository: Zhang, Ning; Zhao, Yun; Zhu, Jinyun; Ma, Quanchao; Wang, Yingchao; Hu, Xinyang; Zhu, Wei; Han, Zhongchao; Yu, Hong (2019), “figshare”, Mendeley Data, V4, http://dx.doi: https://doi.org/10.17632/fp4njbdwt.4

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Cardiology, Second Affiliated Hospital, College of Medicine, Zhejiang University, 88 Jiefang Rd, Hangzhou 310009, Zhejiang Province, People’s Republic of China. 2Cardiovascular Key Laboratory of Zhejiang Province, 88 Jiefang Rd, Hangzhou 310009, Zhejiang Province, People’s Republic of China. 3Beijing Engineering Laboratory of Perinatal Stem Cells, Beijing Institute of Health and Stem Cells, Health & Biotech Co, Beijing 100176, China.

Received: 14 February 2020 Revised: 30 May 2020 Accepted: 18 June 2020 Published online: 08 July 2020

References
1. Hu X, Xu Y, Zhong Z, Wu Y, Zhao J, Wang Y, Cheng H, Kong M, Zhang F, Chen Q, Sun J, Li Q, Jin J, Lu Q, Chen L, Wang C, Zhan H, Fan Y, Yang Q, Yu L, Wu R, Liang J, Zhu J, Wang Y, Jin Y, Lin Y, Yang F, Ji L, Zhu W, Chen J, Yu H, Zhang J, Wang J. A large-scale investigation of hypoxia-preconditioned allogeneic mesenchymal stem cells for myocardial repair in nonhuman Primates: paracrine activity without remuscularization. Circ Res. 2016;118:970–83.
2. Carvalho E, Verma P, Hourigan K, Banerjee R. Myocardial infarction: stem cell transplantation for cardiac regeneration. Regen Med. 2015;10:1025–43.
3. Katsara O, Mahaira LG, Iliopoulou EG, Moustaki A, Antsaklis A, Louridas D, Stefanidis K, Baxevanis CN, Pappamichail M, Perez SA. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2012;21:549–61.
4. Ben Nasr M, Vergani A, Avrukh J, Liu L, Kefaloyianni E, D’Adio F, Tezza S, Corradi D, Bassi R, Valderrama-Vazquez A, Usuelli V, Kim J, Azi J, El Essawy B, Markmann J, Abdi R, Florina P. Co-transplantation of autologous MSCs delays islet allograft rejection and generates a local immunoprivileged site. Acta Diabetol. 2015;52:917–27.
5. Heiss C, Kymel S, Niessler U, Ziemann M, Jelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol. 2005;45:1441–8.
6. Fan M, Chen W, Liu W, Du GQ, Jiang SL, Tian WC, Sun L, Li RK, Tian H. The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res. 2010;13:429–38.
7. Tachibana A, Santosro MR, Mahmoud M, Shukla P, Wang L, Bennett M, Goldstraw AB, Wang M, Fukushima M, Ebert AD, Woo YJ, Bulliston E, Yang PC. Paracrine effects of the pluripotent stem cell-derived cardiac myocytes salvage the injured myocardium. Circ Res. 2017;121:e22–36.
8. Xiao K, Thum T. Exosomal MicroRNAs released by pediatric cardiac progenitor cells. Circ Res. 2017;120:607–9.
9. Nadeau S, Cheng A, Colmegna I, Rodier F. Quantifying senescence-associated phenotypes in primary multipotent mesenchymal stromal cell cultures. Methods Mol Biol. 2019;2045:93–105.
10. Nelson G, Wordsworth J, Wang C, Jurk D, Lawless C, Martin-Ruiz C, von Zglinicki T. A senescent cell bystander effect: senescence-induced senescence. Aging Cell. 2012;11:345–9.
11. Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging (Albany NY). 2012;4:535–46.
12. Wateful HM, Mariani M, Verkaik-Schakel RN, Brouwers-Vos AZ, Schuringa JJ, Vellenga E, de Wolf JT, Huls G. Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:865–71.
13. Barile L, Moccetti T, Martin E, Vasalli G. Roles of exosomes in cardioprotection. Eur Heart J. 2017;38(18):1372–1379.
14. Singla DK, Stem cells and exosomes in cardiac repair. Curr Opin Pharmacol. 2016;27:19–23.
15. Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov I. Umbilical cord as prospective source for mesenchymal stem cell-based therapy. Stem Cells Int. 2016;2016:6901286.
16. Heo JS, Choi Y, Kim HS, Kim HO. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016;37:115–25.
17. Gebert LFR, MacRae U. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2006;7:2114–24.
18. Emanueli C, Sheam AI, Angelini GD, Sahoo S. Exosomes and exosomal miRNAs in cardiovascular protection and repair. Vasc Pharmacol. 2015;71:24–30.
19. J L, Zhang L, Li Y, Guo L, Cao N, Bai Z, Song Y; Xu Z, Zhang J, Liu C, Ma X. miR-136 contributes to pre-eclampsia through its effects on apoptosis and angiogenesis of mesenchymal stem cells. Placenta. 2017;50:102–9.
20. Delgado H, Peschz-Kammerhofer B, Terlecki-Zaniewicz L, Schreiner C, Fortschegger K, Chang MW, Hackl M, Monteforte R, Kuhnel H, Schosserer M, Pulkowski T, Anger M, Fazli S, Paire A, Wien M. High levels of oncomiR-21 contribute to the senescence-induced growth arrest in normal human cells and its knock-down increases the replicative lifespan. Aging Cell. 2013;12:446–58.
21. Moroni MC, Hickman ES, Lazzerini Denchi E, Caprara G, Colli E, Cecconi F, Muller H, Helin K. Apaf-1 is a transcriptional target for E2F and p53. Nat Cell Biol. 2001;3:552–8.
22. Nauta AJ, Westerhuis G, Kruisbeekin AB, Luurink EG, Willermez R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108:2114–20.
23. Lee RH, Sheo MJ, Reger RL, Spees JL, Pulinn AA, Olson SD, Prockop DJ. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A. 2006;103:17438–43.
24. Wakitani S, Mitsuoka T, Nakamura N, Toritsuka Y, Nakamura Y, Horibe S. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. Cell Transplant. 2004;13:595–600.

25. Badillo AT, Beegs KJ, Javazon EH, Tebbets JC, Flake AW. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol Blood Marrow Transplant. 2007;13:412–22.

26. Li Y, Wu Q, Wang Y, Li L, Bu H, Bao J. Senescence of mesenchymal stem cells (review). Int J Mol Med. 2013;37:75–82.

27. Hu X, Wu R, Jiang Z, Wang L, Chen P, Zhang L, Yang L, Wu Y, Chen H, Chen X, Yu X, Zhou Y, Huang X, Webster KA, Yu H, Wang J. Leptin signaling is required for augmented therapeutic properties of mesenchymal stem cells conferred by hypoxia preconditioning. Stem Cells. 2013;32:2702–13.

28. Wu Q, Shao H, Darwin ED, Li J, Li J, Yang B, Webster KA, Yu H. Extracellular calcium increases CXCRI expression on bone marrow-derived cells and enhances pro-angiogenesis therapy. J Cell Mol Med. 2009;13:3764–73.

29. Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell messengers in cardiovascular diseases. Circ Res. 2011;104:177–93.

30. Lawson C, Vicencio JM, Yellen DM, Davidson SM. Microvesicles and exosomes: new players in metabolic and cardiovascular disease. J Endocrinol. 2016;266:R85–71.

31. Kulikarni R, Bajaj M, Ghode S, Jalnapurkar S, Limaye L, Kale VP. Cellular transfer of microvesicles from young mesenchymal stromal cells rejuvenates aged murine hematopoietic stem cells. Stem Cells. 2018;36:420–33.

32. Lei Q, Liu T, Gao F, Xie H, Sun L, Zhao A, Ren W, Guo H, Zhang L, Wang H, Chen Z, Guo YX, Li Q. Microvesicles as potential biomarkers for the identification of senescence in human mesenchymal stem cells. Theranostics. 2017;7:2673–89.

33. Liu S, Mahairaki V, Bai H, Ding Z, Ma, H. Highly purified human extracellular vesicles produced by stem cells alleviate aging cellular phenotypes of senescent human cells. Stem Cells. 2019;37:677–90.

34. Liu H, Sun X, Gong W, Wang G. Human umbilical cord mesenchymal stem cells derived exosomes exert antiapoptosis effect via activating PI3K/Akt/mTOR pathway on H9C2 cells. J Cell Biochem. 2019.

35. Kim YJ, Yoo SM, Park HW, Lim HJ, Kim YL, Lee S, Seo KW, Kang KS. Exosomes derived from human umbilical cord blood mesenchymal stem cells stimulates rejuvenation of human skin. Biochem Biophys Res Commun. 2017;493:1102–8.

36. Hackl M, Brunner S, Fortschegger K, Scheinlin C, Mucicova L, Muck C, Laschober G, Lepperdinger G, Sampson N, Berger P, Hummler-Brandstetter D, Wieser M, Kuhnel H, Strasser A, Rinnerhalter M, Breitenbach M, Milderer M, Eckhart L, Tschachler E, Tost A, Bauer JW, Papak C, Trojanosi Z, Scheideler M, Grillari-Voglauer R, Grubeck-Loebenstein B, Jansen-Durr P, Grillari J. miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human aging. Aging Cell. 2010;9:291–307.

37. Gurunathan S, Kang MH, Jeyaraj M, Qasim M, Kim JH. Review of the isolation, characterization, biological function, and multifarious therapeutic approaches of exosomes. Cells. 2019;8:407.

38. Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY, Kim VN, Kim KS. Human embryonic stem cells express a unique set of microRNAs. Dev Biol. 2004;270:488–98.

39. Shen S, Yue H, Li Y, Qin J, Li K, Liu Y, Wang J. Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. Tumour Biol. 2014;35:631–40.

40. Ding H, Ye ZH, Wen DY, Huang XL, Zeng CM, Mo J, Jiang YQ, Li JJ, Cai XY, Yang H, Chen G. Downregulation of miR1365p in hepatocellular carcinoma is associated with decreased miR-1365p expression and apoptosis of HepG2 cells. Cells. 2017;6:60.

41. Ren H, Qi Y, Yin X, Gao J. miR-136 targets MIEN1 and involves the miR-136 targets MIEN1 and involves the microRNA-mediated regulation of apoptosis. J Cell Mol Med. 2013;15:311–25.

42. Chen Q, Xu J, Li L, Li H, Mao S, Zhang F, Zou K, Zhang CY, Zhang Q. MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis. Cell Death Dis. 2014;5:e1132.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

43. Shakeri R, Kheirollahi A, Davoodi J. Apaf-1: regulation and function in cell death. Biochimie. 2017;135:111–25.

44. Shakeri R, Kheirollahi A, Davoodi J. Apaf-1: regulation and function in cell death. Biochimie. 2017;135:111–25.

45. Lu EP, McLellan M, Ding L, Fulton R, Mardis ER, Wilson RK, Miller CA, Westervelt P, D’Persio JF, Link DC, Walter MJ, Ley TJ, Graubert TA. Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. Blood. 2004;124:3887–95.